FDA Approved: LAMICTAL — Supplemental Application (GlaxoSmithKline LLC)

View source ↗

Summary

FDA approved a supplemental application for LAMICTAL (lamotrigine) from GlaxoSmithKline, updating the product labeling as a result of the supplemental filing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Epilepsy

Drugs mentioned

• LAMICTAL (LAMOTRIGINE)

Snippet

SUPPL AP for LAMICTAL (LAMOTRIGINE)